Drug guidance
Ivabradine for the treatment of chronic stable angina and chronic heart failure
Condition
Cardiovascular
5 February 2018
Published on 05 Feb 2018
Last Updated on 05 Feb 2018
Guidance Recommendations
The Ministry of Health's Drug Advisory Committee has recommended:
Ivabradine 5mg and 7.5mg tablets for the treatment of chronic heart failure in patients:
with New York Heart Association (NYHA) class II to IV stable chronic heart failure with systolic dysfunction (LVEF of 35% or less);
who are in sinus rhythm with a heart rate of 75 bpm or more and
who are given concomitant standard medical management with maximum tolerated doses of beta blockers, angiotensin-converting enzyme inhibitors and aldosterone antagonists, unless contraindicated.
Subsidy status
Ivabradine 5mg and 7.5mg tablets are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication.
MAF assistance does not apply to the use of ivabradine for chronic stable angina.
Ivabradine for the treatment of CSA and CHF (5 Feb 2018) [PDF, 487 KB]